Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose psilocybin vs niacin in major depressive disorder with PET synaptic density assessment
2020-002790-94Phase 2Completed
- Sponsor
- SLSO
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Psilocybin 25 mg with Niacin active placebo (2 arms). Primary endpoint: Change in depressive symptom severity. Started Jun 2020; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2020-002790-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002790-94.